Therapeutic strategies for C9 ALS/FTD. Given multiple lines of evidence supporting the gain of function of C9 expansion RNAs and the toxicity of C9 RAN dipeptide proteins, therapeutic approaches targeting expansion RNAs and C9 RAN proteins were developed and tested in disease models. This evidence concerns the gene RAN and frontotemporal dementia.